Cancer Biology & Medicine (Dec 2019)
Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
- Yuxiang Wang,
- Xian Li,
- Xueling Liu,
- Yi Chen,
- Chunhao Yang,
- Cun Tan,
- Bobo Wang,
- Yiming Sun,
- Xi Zhang,
- Yinglei Gao,
- Jian Ding,
- Linghua Meng
Affiliations
- Yuxiang Wang
- Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- Xian Li
- Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- Xueling Liu
- Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- Yi Chen
- University of Chinese Academy of Sciences, Beijing 100049, China
- Chunhao Yang
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200120, China
- Cun Tan
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200120, China
- Bobo Wang
- Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- Yiming Sun
- University of Chinese Academy of Sciences, Beijing 100049, China
- Xi Zhang
- Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- Yinglei Gao
- University of Chinese Academy of Sciences, Beijing 100049, China
- Jian Ding
- University of Chinese Academy of Sciences, Beijing 100049, China
- Linghua Meng
- Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2019.0401
- Journal volume & issue
-
Vol. 16,
no. 4
pp. 836 – 836
Abstract
No abstracts available.
